Syndax Pharma (SNDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 130,893 | 134,930 | 116,808 | 108,636 | 153,993 |
| Marketable Securities | 230,346 | 278,756 | 337,366 | 360,070 | 362,320 |
| Receivables | 58,890 | 68,145 | 41,139 | 35,399 | 19,312 |
| Inventories | 34,948 | 32,754 | 25,000 | 17,696 | 4,664 |
| TOTAL | $471,177 | $528,081 | $529,830 | $531,676 | $548,751 |
| Non-Current Assets | |||||
| PPE Net | 177 | 181 | 128 | N/A | N/A |
| Investments And Advances | 0 | 0 | 20,146 | 62,627 | 89,938 |
| Other Non-Current Assets | 1,314 | 1,444 | 1,688 | 1,846 | 2,018 |
| TOTAL | $1,491 | $1,625 | $21,962 | $64,473 | $91,956 |
| Total Assets | $472,668 | $529,706 | $551,792 | $596,149 | $640,707 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | 22,925 | 19,435 | 14,149 |
| Accounts payable and accrued liabilities | 10,843 | 16,580 | 13,826 | 22,136 | 24,037 |
| Accrued Expenses | 74,843 | 103,064 | 77,105 | 71,066 | 55,981 |
| TOTAL | $86,174 | $120,116 | $114,187 | $112,987 | $94,551 |
| Non-Current Liabilities | |||||
| Long Term Debt | 343,965 | 343,909 | 320,985 | 324,413 | 329,644 |
| Other Non-Current Liabilities | 907 | 1,051 | 1,190 | 1,325 | 1,453 |
| TOTAL | $344,872 | $344,960 | $322,175 | $325,738 | $331,097 |
| Total Liabilities | $431,046 | $465,076 | $436,362 | $438,725 | $425,648 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 88,610 | 88,201 | 86,915 | 86,142 | 86,047 |
| Common Shares | 9 | 9 | 9 | 9 | 9 |
| Retained earnings | -1,549,253 | -1,506,580 | -1,438,566 | -1,377,851 | -1,306,004 |
| Other shareholders' equity | 11 | 452 | 525 | 285 | 527 |
| TOTAL | $41,622 | $64,630 | $115,430 | $157,424 | $215,059 |
| Total Liabilities And Equity | $472,668 | $529,706 | $551,792 | $596,149 | $640,707 |